Frontier IP, notes the following announcement from portfolio company Exscientia plc ("Exscientia" or the "Company") of a new collaboration with Merck KGaA, Darmstadt, Germany, ("Merck") focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology. Under the terms of the agreement, Exscientia will receive an upfront cash payment of $20 million from Merck and will be eligible for discovery, development, regulatory and sales-based milestone payments of up to $674 million in aggregate if all milestones for three initial programmes are achieved. Frontier IP holds a 0.4% equity stake in Exscientia.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.375 USD | +1.42% | +13.03% | -16.07% |
21/05 | Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon | MT |
21/05 | Exscientia to Reduce Up to 25% Workforce by Year End | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.07% | 670M | |
+45.45% | 54.63B | |
-6.96% | 39.92B | |
+37.07% | 38.82B | |
+13.17% | 26.86B | |
-11.17% | 26.22B | |
-21.90% | 18.78B | |
+24.95% | 12.21B | |
+0.32% | 12.16B | |
+24.93% | 11.94B |
- Stock Market
- Equities
- EXAI Stock
- News Exscientia plc
- Exscientia Announces Collaboration with Merck